专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2017082017A 補体のインヒビターによる発作性夜間血色素尿症患者の処置审中-公开
公开(公告)号：JP2017082017A
公开(公告)日：2017-05-18
申请号：JP2017028811
申请日：2017-02-20
申请人：アレクシオンファーマシューティカルズ, インコーポレイテッド , Alexion Pharmaceuticals Inc , アレクシオンファーマシューティカルズ, インコーポレイテッド
发明人： REONARD BELL , ROTHER RUSSELL P
IPC分类号： A61K45/00 , A61P13/02
CPC分类号： C07K16/18 , A61K9/0019 , A61K31/7105 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565
摘要：【課題】補体のインヒビターによる発作性夜間血色素尿症患者の処置の提供。【解決手段】エクリズマブ(終末補体活性化を阻害するC5に対するヒト化モノクローナル抗体)は、発作性夜間血色素尿症(PNH)患者の小さなコホートにおいて予備的な12週間のオープンラベル試験において活性を示した。本治験は、多施設共同二重盲検無作為化プラセボ対照国際共同第III相試験において、長期のエクリズマブによる治療が、脈管内溶血を低減させることができるか、ヘモグロビンレベルを安定させることができるか、輸血の必要性を低下させることができるか、及びクオリティオブライフを改善することができるかを検討したものである。エクリズマブは、脈管内溶血の減少により、ヘモグロビンレベルを安定させ、輸血の必要性を低下させ、及びPNH患者のクオリティオブライフを改善したことが見出された。【選択図】なし

2. 发明专利

JP2014080438A Prolongation of survival of allograft by inhibiting complement activity 审中-公开
标题翻译：通过抑制补充活动来扩大合成酶
公开(公告)号：JP2014080438A
公开(公告)日：2014-05-08
申请号：JP2014021907
申请日：2014-02-07
申请人： Alexion Pharmaceuticals Inc , アレクシオンファーマシューティカルズ, インコーポレイテッド
发明人： ROTHER RUSSELL P , WANG HAO , ZHONG ZHEN
IPC分类号： A61K45/06 , A61K31/675 , A61K38/00 , A61K39/395 , A61P37/06 , A61P43/00 , C07K16/18
CPC分类号： C07K16/18 , A61K2039/505
摘要： PROBLEM TO BE SOLVED: To provide methods and medicaments for prolonging survival of an allograft.SOLUTION: Methods of prolonging survival of transplanted cells, tissues or organs are provided. In particular, methods of prolonging survival of allotransplanted cells, tissues or organs are provided. These methods are directed to using one or more immunosuppressants in addition to an inhibitor of complement activity. Use of one or more immunosuppressants and an inhibitor of complement activity in manufacture of one or more medicaments or medicament packages is also provided. Such medicaments or medicament packages are useful in prolonging survival of an allograft in a subject mammal.
摘要翻译：要解决的问题：提供延长同种异体移植物存活的方法和药物。解决方案：提供延长移植细胞，组织或器官存活的方法。特别地，提供延长异体移植细胞，组织或器官存活的方法。这些方法涉及除补体活性抑制剂之外还使用一种或多种免疫抑制剂。还提供了一种或多种免疫抑制剂和补体活性抑制剂在制备一种或多种药物或药物包装中的用途。这样的药物或药物包装可用于延长受试哺乳动物中同种异体移植物的存活。

3. 发明专利

JP2013163695A Antibody to cd200 and use in immune response 有权
标题翻译： CD200抗体和免疫应答使用
公开(公告)号：JP2013163695A
公开(公告)日：2013-08-22
申请号：JP2013110577
申请日：2013-05-27
申请人： Alexion Pharmaceuticals Inc , アレクシオンファーマシューティカルズ, インコーポレイテッド
发明人： ROTHER RUSSELL P , FAAS MCKNIGHT SUSAN
IPC分类号： A61K45/06 , A61K31/436 , A61K38/00 , A61K39/395 , A61P37/06 , A61P43/00
CPC分类号： C07K16/2803 , A61K39/39541 , A61K2039/505 , C07K2317/52 , A61K2300/00
摘要： PROBLEM TO BE SOLVED: To provide methods and compositions for inhibiting immune responses by inhibiting the interaction between CD200 and CD200R.SOLUTION: The disclosure also is methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival by inhibiting the interaction between CD200 and CD200R. In certain embodiments, the disclosure provides a method for inhibiting a humoral immune response in a subject in need of inhibiting the humoral immune response, wherein the method comprises a step of administering to the subject an effective amount of an anti-CD200 antibody or antigen-binding fragment thereof and further comprises a step of administering to the subject an immunomodulatory agent or immunosuppressive agent.
摘要翻译：要解决的问题：通过抑制CD200和CD200R之间的相互作用来提供抑制免疫反应的方法和组合物。本发明还涉及通过抑制CD200和CD200R之间的相互作用来抑制移植物排斥和促进或延长移植物存活的方法和组合物。在某些实施方案中，本公开提供了抑制需要抑制体液免疫应答的受试者体液免疫应答的方法，其中所述方法包括向受试者施用有效量的抗CD200抗体或抗原 - 其还包括向受试者施用免疫调节剂或免疫抑制剂的步骤。

4. 发明专利

JP2005185286A Composition and method for treating glomerulonephritis and other inflammation diseases 有权
标题翻译：用于治疗糖尿病和其他炎症疾病的组合物和方法
公开(公告)号：JP2005185286A
公开(公告)日：2005-07-14
申请号：JP2005012176
申请日：2005-01-19
申请人： Alexion Pharmaceuticals Inc , アレクシオンファーマシューティカルズ, インコーポレイテッド
发明人： EVANS MARK J , MATIS LOUIS , MUELLER EILEEN ELLIOTT , NYE STEVEN H , ROLLINS SCOTT , ROTHER RUSSELL P , SPRINGHORN JEREMY P , SQUINTO STEPHEN P , THOMAS THOMAS C , WANG YI , WILKINS JAMES A
IPC分类号： A01K67/027 , A61K38/00 , A61K39/395 , A61P13/02 , A61P13/12 , A61P15/00 , A61P29/00 , A61P37/02 , A61P37/06 , C07H21/04 , C07K14/47 , C07K14/75 , C07K16/06 , C07K16/18 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/02 , C12N15/09 , C12P21/02 , C12P21/08 , G01N33/53
CPC分类号： C07K14/472 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/622 , C07K2319/00
摘要： PROBLEM TO BE SOLVED: To provide a new means for reducing glomerular inflammations and renal insufficiency entrained thereafter. SOLUTION: A nucleic acid molecule comprising a nucleotide sequence encoding scFv polypeptide containing amino acid sequence corresponding to amino acid 1-248 having a specific sequence, a nucleic acid molecule comprising a nucleotide sequence encoding polypeptide containing variable light chain domain amino acid sequence corresponding to amino acid 3 to amino acid 110 having a specific sequence, a nucleic acid molecule comprising a nucleotide sequence encoding polypeptide containing variable heavy chain domain amino acid sequence corresponding to amino acid 1 to amino acid 122 having a specific sequence, and a protein containing (a) the first polypeptide domain containing the valuable light chain domain amino acid sequence corresponding to amino acid 3 to amino acid 110 having the specific sequence and (b) the second polypeptide domain containing the valuable heavy chain domain amino acid sequence corresponding to amino acid 1 to amino acid 122 having the specific sequence, are provided. COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：要解决的问题：提供一种减少肾小球炎症和其他手术后肾功能不全的新手段。解决方案：包含编码具有对应于具有特定序列的氨基酸1-248的氨基酸序列的scFv多肽的核苷酸序列的核酸分子，包含编码含有可变轻链结构域氨基酸序列的多肽的核苷酸序列的核酸分子对应于具有特定序列的氨基酸3至氨基酸110，核酸分子包含编码对应于具有特定序列的氨基酸1至氨基酸122的可变重链结构域氨基酸序列的多肽的核苷酸序列，以及含有（a）含有对应于具有特定序列的氨基酸3至氨基酸110的有价值的轻链结构域氨基酸序列的第一多肽结构域和（b）含有对应于氨基酸的有价值的重链结构域氨基酸序列的第二多肽结构域 1至具有特定顺序的氨基酸122 ided。版权所有（C）2005，JPO＆NCIPI

5. 发明专利

JP2013155202A Prolongation of survival of allograft by inhibiting complement activity 审中-公开
标题翻译：通过抑制补充活动来扩大合成酶
公开(公告)号：JP2013155202A
公开(公告)日：2013-08-15
申请号：JP2013105946
申请日：2013-05-20
申请人： Alexion Pharmaceuticals Inc , アレクシオンファーマシューティカルズ, インコーポレイテッド
发明人： ROTHER RUSSELL P , WANG HAO , CHEN CHON
IPC分类号： A61K45/06 , A61K31/164 , A61K31/343 , A61K31/42 , A61K31/436 , A61K31/47 , A61K31/519 , A61K31/52 , A61K31/573 , A61K31/675 , A61K31/7056 , A61K31/706 , A61K38/00 , A61K39/395 , A61P13/12 , A61P37/06 , A61P43/00
CPC分类号： C07K16/18 , A61K31/16 , A61K31/365 , A61K31/573 , A61K38/13 , A61K2039/505
摘要： PROBLEM TO BE SOLVED: To provide prolongation of survival of an allograft by inhibiting complement activity.SOLUTION: There are provided methods of prolonging survival of allotransplanted cells, tissues or organs. These methods are directed to administering to the allograft recipient an inhibitor of complement activity together with one or more immunosuppressants and/or immunosuppressive methods. The inhibitor of complement activity is administered chronically. These methods have been determined to aid in preventing chronic rejection of allografts. These methods can additionally be used in cases in which the recipient has been presensitized to the allograft or in which there is an ABO mismatch between the allograft and the recipient.
摘要翻译：要解决的问题：通过抑制补体活性来提供同种异体移植物的存活延长。解决方案：提供延长异体移植细胞，组织或器官存活的方法。这些方法涉及向同种异体移植受体施用补体活性的抑制剂以及一种或多种免疫抑制剂和/或免疫抑制方法。补体活性抑制剂长期施用。已经确定了这些方法以帮助预防同种异体移植物的慢性排斥反应。这些方法可以另外用于接受者已经被同化异体移植或同种异体移植物与受体之间存在ABO不匹配的情况。

6. 发明专利

JP2009165471A Composition and method for treating glomerulonephritis and other inflammatory diseases 有权
标题翻译：用于治疗糖尿病和其他炎症疾病的组合物和方法
公开(公告)号：JP2009165471A
公开(公告)日：2009-07-30
申请号：JP2009001080
申请日：2009-01-06
申请人： Alexion Pharmaceuticals Inc , アレクシオンファーマシューティカルズ, インコーポレイテッド
发明人： EVANS MARK J , MATIS LOUIS , MUELLER EILEEN ELLIOTT , NYE STEVEN H , ROLLINS SCOTT , ROTHER RUSSELL P , SPRINGHORN JEREMY P , SQUINTO STEPHEN P , THOMAS THOMAS C , WANG YI , WILKINS JAMES A
IPC分类号： A01K67/027 , C12N15/09 , A61K38/00 , A61K39/395 , A61P7/00 , A61P13/02 , A61P13/12 , A61P15/00 , A61P29/00 , A61P37/02 , A61P37/06 , C07H21/04 , C07K14/47 , C07K14/75 , C07K16/06 , C07K16/18 , C07K16/44 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/02 , C12P21/02 , C12P21/08 , G01N33/15 , G01N33/50 , G01N33/53
CPC分类号： C07K14/472 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/622 , C07K2319/00
摘要： PROBLEM TO BE SOLVED: To provide a new approach for reducing glomerular inflammation and renal dysfunction associated with glomerulonephritis (GN). SOLUTION: Disclosed are: a nucleic acid molecule comprising a nucleotide sequence encoding scFv polypeptide containing a specific amino acid sequence; a nucleic acid molecule comprising a nucleotide sequence encoding polypeptide containing a specific variable light chain region amino acid sequence corresponding to amino acid 3 to amino acid 110; a nucleic acid molecule comprising a nucleotide sequence encoding polypeptide containing a specific variable heavy chain region amino acid sequence corresponding to amino acid 1 to amino acid 122; or an isolated protein comprising (a) a first polypeptide region containing a specific variable light chain region amino acid sequence corresponding to amino acid 3 to amino acid 110 and (b) a second polypeptide region containing a specific variable heavy chain region amino acid sequence corresponding to amino acid 1 to amino acid 122. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：提供减少与肾小球肾炎（GN）相关的肾小球炎症和肾功能障碍的新方法。解决方案：公开了包含编码含有特定氨基酸序列的scFv多肽的核苷酸序列的核酸分子; 核酸分子，其包含编码含有对应于氨基酸3至氨基酸110的特异性可变轻链区氨基酸序列的多肽的核苷酸序列; 包含编码含有对应于氨基酸1至氨基酸122的特异性可变重链区氨基酸序列的多肽的核苷酸序列的核酸分子; 或分离的蛋白质，其包含（a）含有对应于氨基酸3至氨基酸110的特异性可变轻链区氨基酸序列的第一多肽区和（b）含有对应于特定可变重链区氨基酸序列的第二多肽区至氨基酸1至氨基酸122.版权所有（C）2009，JPO＆INPIT

7. 发明专利

JP2006020633A Composition and method for treating glomerulonephritis and other inflammation disease 审中-公开
标题翻译：用于治疗糖尿病和其他炎症疾病的组合物和方法
公开(公告)号：JP2006020633A
公开(公告)日：2006-01-26
申请号：JP2005198116
申请日：2005-07-06
申请人： Alexion Pharmaceuticals Inc , アレクシオンファーマシューティカルズ, インコーポレイテッド
发明人： EVANS MARK J , MATIS LOUIS , MUELLER EILEEN ELLIOTT , NYE STEVEN H , ROLLINS SCOTT , ROTHER RUSSELL P , SPRINGHORN JEREMY P , SQUINTO STEPHEN P , THOMAS THOMAS C , WANG YI , WILKINS JAMES A
IPC分类号： A01K67/027 , C12N15/09 , A61K38/00 , A61K39/395 , A61P13/02 , A61P13/12 , A61P15/00 , A61P29/00 , A61P37/02 , A61P37/06 , C07H21/04 , C07K14/47 , C07K14/75 , C07K16/06 , C07K16/18 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/02 , C12P21/02 , C12P21/08 , G01N33/15 , G01N33/50 , G01N33/53
CPC分类号： C07K14/472 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/622 , C07K2319/00
摘要： PROBLEM TO BE SOLVED: To provide a new approach for reducing glomerular inflammation and renal insufficiency entrained thereafter. SOLUTION: The invention provides (1) a nucleic acid molecule containing a nucleotide sequence encoding an scFv polypeptide containing an amino acid sequence corresponding to specific 248 residues, (2) a nucleic acid molecule containing a nucleotide sequence encoding a polypeptide containing a variable light-chain region amino acid sequence corresponding to specific 108 residues, (3) a nucleic acid molecule containing a nucleotide sequence encoding a polypeptide containing a variable heavy-chain region amino acid sequence corresponding to specific 122 residues, and (4) a isolated protein containing (a) the 1st polypeptide region containing a variable light-chain region amino acid sequence corresponding to the term (2) and (b) the 2nd polypeptide region containing a variable heavy-chain region amino acid sequence corresponding to the term (3). COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：要解决的问题：提供一种减少肾小球炎症和其他手术后肾功能不全的新方法。解决方案：本发明提供（1）含有编码包含对应于特定248个残基的氨基酸序列的scFv多肽的核苷酸序列的核酸分子，（2）含有编码含有可变轻链区氨基酸序列对应于特定的108个残基，（3）含有编码含有对应于特定122个残基的可变重链区氨基酸序列的多肽的核苷酸序列的核酸分子，和（4）含有（a）含有对应于术语（2）的可变轻链区氨基酸序列的第一多肽区和（b）含有对应于术语（3）的可变重链区氨基酸序列的第二多肽区）。版权所有（C）2006，JPO＆NCIPI

8. 发明专利

JP2013213044A Method of treating hemolytic disease 有权
标题翻译：治疗HEMOLYTIC疾病的方法
公开(公告)号：JP2013213044A
公开(公告)日：2013-10-17
申请号：JP2013145341
申请日：2013-07-11
申请人： Alexion Pharmaceuticals Inc , アレクシオンファーマシューティカルズ, インコーポレイテッド
发明人： BELL LEONARD , ROTHER RUSSELL P
IPC分类号： A61K39/395 , A61K45/00 , A61K48/00 , A61P7/00 , A61P7/06
CPC分类号： A61K45/06 , A61K39/39541 , A61K2039/545 , A61K2300/00
摘要： PROBLEM TO BE SOLVED: To provide a composition for recovery of nitrogen monoxide (NO) homeostasis in a subject and a composition for alleviating hemoglobinuria in a subject.SOLUTION: A composition for recovery of nitrogen monoxide (NO) homeostasis, includes a molecule selected from the group consisting of (a) a molecule which binds to one or more complement components, (b) a molecule which blocks the generation of one or more complement components, and (c) a molecule which blocks the activity of one or more complement components. A composition for alleviating hemoglobinuria in a subject, includes erythropoietin (EPO) and a molecule including a molecule selected from the group consisting of (a) a molecule which binds to one or more complement components, (b) a molecule which blocks the generation of one or more complement components, and (c) a molecule which blocks the activity of one or more complement components.
摘要翻译：要解决的问题：提供用于回收受试者中的一氧化氮（NO）体内平衡的组合物和用于缓解受试者血红蛋白尿的组合物。解决方案：用于回收一氧化氮（NO）体内平衡的组合物，包括选自由（a）与一种或多种补体成分结合的分子，（b）阻断一种或多种补体成分的产生的分子，和（c）阻断一种或多种补体成分的活性的分子。用于缓解受试者血红蛋白尿的组合物包括促红细胞生成素（EPO）和包括选自以下的分子的分子：（a）与一种或多种补体成分结合的分子，（b）阻断产生一种或多种补体组分，和（c）阻断一种或多种补体组分的活性的分子。

9. 发明专利

JP2012095650A Composition and method for treating glomerulonephritis and other inflammatory diseases 审中-公开
标题翻译：用于治疗糖尿病和其他炎症疾病的组合物和方法
公开(公告)号：JP2012095650A
公开(公告)日：2012-05-24
申请号：JP2011248008
申请日：2011-11-11
申请人： Alexion Pharmaceuticals Inc , アレクシオンファーマシューティカルズ, インコーポレイテッド
发明人： EVANS MARK J , MATIS LOUIS , MUELLER EILEEN ELLIOTT , NYE STEVEN H , ROLLINS SCOTT , ROTHER RUSSELL P , SPRINGHORN JEREMY P , SQUINTO STEPHEN P , THOMAS THOMAS C , WANG YI , WILKINS JAMES A
IPC分类号： A01K67/027 , C12N15/09 , A61K38/00 , A61K39/395 , A61P7/00 , A61P13/02 , A61P13/12 , A61P15/00 , A61P29/00 , A61P37/02 , A61P37/06 , C07H21/04 , C07K14/47 , C07K14/75 , C07K16/06 , C07K16/18 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/02 , C12P21/02 , C12P21/08 , G01N33/15 , G01N33/50 , G01N33/53
CPC分类号： C07K14/472 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/622 , C07K2319/00
摘要： PROBLEM TO BE SOLVED: To provide a new approach for reducing glomerular inflammation and renal dysfunction associated with glomerulonephritis (GN).SOLUTION: There are provided: a nucleic acid molecule comprising a nucleotide sequence encoding scFv polypeptide containing a specific amino acid sequence; a nucleic acid molecule comprising a nucleotide sequence encoding polypeptide containing a specific variable light chain region amino acid sequence corresponding to amino acid 3 to amino acid 110; a nucleic acid molecule comprising a nucleotide sequence encoding polypeptide containing a specific variable heavy chain region amino acid sequence corresponding to amino acid 1 to amino acid 122; or an isolated protein comprising (a) a first polypeptide region containing a specific variable light chain region amino acid sequence corresponding to amino acid 3 to amino acid 110 and (b) a second polypeptide region containing a specific variable heavy chain region amino acid sequence corresponding to amino acid 1 to amino acid 122.
摘要翻译：要解决的问题：提供减少与肾小球肾炎（GN）相关的肾小球炎症和肾功能障碍的新方法。提供：提供了包含编码含有特定氨基酸序列的scFv多肽的核苷酸序列的核酸分子; 核酸分子，其包含编码含有对应于氨基酸3至氨基酸110的特定可变轻链区氨基酸序列的多肽的核苷酸序列; 包含编码含有对应于氨基酸1至氨基酸122的特异性可变重链区氨基酸序列的多肽的核苷酸序列的核酸分子; 或分离的蛋白质，其包含（a）含有对应于氨基酸3至氨基酸110的特异性可变轻链区氨基酸序列的第一多肽区和（b）含有对应于特定可变重链区氨基酸序列的第二多肽区至氨基酸1至氨基酸122.版权所有（C）2012，JPO＆INPIT

10. 发明专利

JP2014015484A Treatment of paroxysmal nocturnal hemoglobinuria patient by inhibitor of complement 审中-公开
标题翻译：通过补充抑制剂治疗寄生虫病人血红蛋白血症患者
公开(公告)号：JP2014015484A
公开(公告)日：2014-01-30
申请号：JP2013219882
申请日：2013-10-23
申请人： Alexion Pharmaceuticals Inc , アレクシオンファーマシューティカルズ, インコーポレイテッド
发明人： REONARD BELL , ROTHER RUSSELL P
IPC分类号： A61K45/00 , A61K31/56 , A61K31/7105 , A61K31/711 , A61K31/713 , A61K38/00 , A61K39/395 , A61K48/00 , A61P3/02 , A61P7/06 , A61P13/02
CPC分类号： C07K16/18 , A61K9/0019 , A61K31/7105 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565
摘要： PROBLEM TO BE SOLVED: To provide treatment of a paroxysmal nocturnal hemoglobinuria patient by an Inhibitor Of complement.SOLUTION: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether long-term chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis.
摘要翻译：要解决的问题：通过补体抑制剂提供对阵发性夜间血红蛋白尿患者的治疗。解决方案：抑制末端补体激活的针对C5的人源化单克隆抗体Eculizumab在初步的12周开放标签试验中显示出活性阵发性夜间血红蛋白尿症（PNH）的小队列。本研究检查长期慢性eculizumab治疗是否可以减少血管内溶血，稳定血红蛋白水平，降低输血需求，并提高双盲，随机，安慰剂对照，多中心全球III期试验的生活质量。已经发现，通过减少血管内溶血，厄库珠单抗稳定了血红蛋白水平，降低了输血的需要，并改善PNH患者的生活质量。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式